News Story: Full Text
Sponsored By
Gleolan for brain tumors
Please Click On The Above Banner For More Details
Braintumor Website


Peregrine Announces Quarterly Conference Call (Business Wire) ...~~~ These technologies target cell structures and cell types that are common among solid tumor cancers, giving them broad applicability across various tumor types....... is currently in a multi-center Phase II clinical study for the treatment of brain cancer and in four Phase I clinical trials for the treatment of colorectal,... - Sep 05 12:01 PM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/bw/010905/50345.html

Posted on: 09/05/2001

"Yahoo - Peregrine Announces Quarterly Conference Call"
Yahoo! Finance Finance Home - Yahoo! - Help
Business Wire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
PPHM
1.5
+0.08
delayed 20 mins - disclaimer

Wednesday September 5, 12:01 pm Eastern Time

Press Release

SOURCE: Peregrine Pharmaceuticals

Peregrine Announces Quarterly Conference Call

TUSTIN, Calif.--(BUSINESS WIRE)--Sept. 5, 2001--Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM - news) today announced that it will conduct its quarterly conference call on Monday, Sept. 10 at 11 a.m. (EST).

In order to participate in this call, phone 800/314-7867 at least five minutes before the call is scheduled to begin. An audio replay will be available afterwards at 888/203-1112 (code No. 400696) as well as on Peregrine's Web site, http://www.peregrineinc.com.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals is a biopharmaceutical company focused on the development, commercialization, and licensing of unique technologies for the treatment of cancer, primarily based on its "collateral targeting technologies." These technologies target cell structures and cell types that are common among solid tumor cancers, giving them broad applicability across various tumor types. In clinical and pre-clinical studies, collateral targeting technologies have been shown to deliver various anti-cancer compounds selectively to the tumor site without causing damage to surrounding healthy tissue.

The company has three collateral targeting technologies: Tumor Necrosis Therapy (TNT), Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents (VTA). The company's lead anti-cancer drug, Cotara(TM), is currently in a multi-center Phase II clinical study for the treatment of brain cancer and in four Phase I clinical trials for the treatment of colorectal, pancreas, liver, and soft tissue sarcoma and biliary cancers.

The company also has a direct tumor targeting agent called Oncolym® for the treatment of advanced non-Hodgkin's B-cell Lymphoma which is currently in a multi-center Phase I/II. Copies of Peregrine news releases, SEC filings and other valuable information for investors may be found on the company's Web site at http://www.peregrineinc.com.

Safe Harbor Statement: This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ from the company's expectations as a result of risk factors discussed in Peregrine's reports on file with the U.S. Securities and Exchange Commission, including, but not limited to, the company's report on Form 10-K for the year ended April 30, 2001.


Contact:
     Susan E. Atkins & Associates
     Alex Boese (Media) 858/860-0266
     www.irpr.com
          or
     Hawk Associates Inc.
     Frank Hawkins (Investor) 305/852-2383
     www.hawkassociates.com

Email this story - Most-emailed articles - Most-viewed articles


More Quotes and News:Peregrine Pharmaceuticals Inc (NasdaqSC:PPHM - news)
Related News Categories: biotech, health care, medical/pharmaceutical

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Questions or Comments?
"


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740